
eMind Partners with Alfresa Corporation in Capital and Business Alliance: Advancing Real-World Deployment of Digital Health Services Powered by eMind's Proprietary AI through a Nationwide Healthcare Network

Combining AI and Digital Phenotyping Technology with a Foundation in the Ethical Pharmaceuticals Wholesaling Business to Accelerate the Social Implementation of Next-Generation Digital Health Services in Patients' Daily Lives

eMind, Inc. (head office: Chiyoda-ku, Tokyo; Chief Executive Officer: David Liebreich; hereinafter “eMind”), a company developing digital health technologies and services powered by smartphones and AI — with a focus on mental health and neurological/psychiatric conditions including depression, epilepsy, migraine, ALS (amyotrophic lateral sclerosis), and other intractable neurological diseases - is pleased to announce that it has raised approximately JPY 350 million by way of a third-party allotment of new shares to Alfresa Corporation (head office: Chiyoda-ku, Tokyo; representative director & president: Yusuke Fukujin; hereinafter “Alfresa”), a company engaged in the Ethical Pharmaceuticals Wholesaling Business. The two companies entered into a capital and business alliance agreement on June 12, 2026.

Toward the Real-World Implementation of Patient Support Through Digital Health Services

In the areas of mental health and neurological/psychiatric conditions, shortage of specialist physicians and limited consultation time create structural barriers to continuously monitoring day-to-day changes in patients' conditions during "care gaps" - the periods between clinic visits or before initial diagnosis. The resulting lack of information on daily changes can contribute to delayed early detection of disease, insufficient monitoring of treatment progress and medication adherence, and delays in connecting patients to appropriate care and support.

To address these challenges, eMind fulfills its mission to "support people's physical and mental health and contribute to society" by developing digital health services that analyze smartphone-derived behavioral and lifestyle data using AI. With digital therapeutics in view, eMind is developing a range of digital health services, including disease awareness and screening tools, patient support applications, and clinical decision support systems. In parallel, the company is validating the clinical relevance of these technologies through joint research with universities and pharmaceutical companies^{*1}. eMind has also launched "eMind for Business", a well-being support application for corporate users, and is exploring its applicability to employee health management and workplace mental health through proof-of-concept (PoC) projects at corporations and university hospitals.

The Alfresa Group has adopted the solutions business as a growth area under 25–27 Mid-term Management Plan Vision 2032 Stage 2: Pioneering the Future with Our Collective Strength^{*2}. In the

Ethical Pharmaceuticals Wholesaling Business, the Group is developing and deploying various products and services^{*3} aimed at enhancing convenience for patients and medical institutions through health technology and at providing solutions for pharmaceutical companies.

Both companies have been exploring the potential of new solutions by combining their respective management resources. Through this process, they reached a shared understanding that integrating eMind's proprietary digital health services with Alfresa's business foundation as a pharmaceutical wholesaler - including its extensive network of relationships with healthcare institutions and pharmaceutical companies - would generate new social value. This shared conviction led to the conclusion of the present capital and business alliance.

Furthermore, both companies will jointly promote the practical social implementation of solutions that contribute to the advancement of healthcare and will work to help improve the quality of healthcare and patients' quality of life.

Key Areas of Business Collaboration

- Exploring the potential to deploy digital health services for medical use that target migraines and ALS in pharmaceutical companies and other settings
- Leveraging Alfresa's network of medical institutions and pharmaceutical manufacturers to promote the introduction and use of digital health services developed and offered by eMind
- Exploring the joint development and commercialization of new digital therapeutics and digital health services

*1 Reference:

eMind, Tohoku University, and Otsuka Pharmaceutical Launch Epilepsy Smart Medical Joint Research Project (Phase II) Aiming to Start and Expand Epilepsy Treatment Support System (published on July 3, 2025)

<https://emind.jp/wp-content/uploads/2025/07/eMind-Tohoku-University-and-Otsuka-Pharmaceutical-Launch-Epilepsy-Smart-Medical-Joint-Research-Project-Phase-II-Aiming-to-Start-and-Expand-Epilepsy-Treatment-Support-System.pdf>

eMind and St. Marianna University School of Medicine Enter into a Comprehensive Partnership Agreement to Accelerate Next-Generation Medical Innovation in SaMD and Non-SaMD Fields Through Proprietary AI Technology (published on April 28, 2026)

<https://prtimes.jp/main/html/rd/p/000000013.000111093.html> (Japanese only)

*2 Reference: Notice Regarding the Formulation of the 25-27 Mid-term Management Plan Vision 2032 Stage 2: Pioneering the Future with Our Collective Strength (published on May 15, 2025 on the Alfresa Holdings Corporation corporate website)

https://ssl4.eir-parts.net/doc/2784/ir_material17/250645/00.pdf

*3 Products and services: System tools that are planned, developed, and provided by the Alfresa Group to help solve issues for stakeholders